Browsing by Author "Estevinho, F."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- 108P PICTuRE: Real-world treatment pathways in stage III non-small cell lung cancer in PortugalPublication . Teixeira, M.E.; Oliveira Fernandes, M.G.; Ferreira, M.L.S.; Estevinho, F.; Lopes, J.A.; Araújo, A.; Pacheco Figueiredo, M.M.; Barradas Lopes, M.L.; Lopes, M.; Brito, U.; Barroso, A.M.P.; Camacho, C.; Parente, B.; Felizardo, M.M.; Meleiro, A.; Bernardo, M.; Bernardo, F.; Figueiredo, S.Stage III NSCLC is a heterogeneous and complex setting that requires multimodal management. Recent advances in modern medicine led to the implementation of immuno-oncology (IO) into clinical practice. PICTuRE aims to assess the clinical management and the IO impact on clinical outcomes in stage III NSCLC patients (pts).
- Improving non-small-cell lung cancer survival through molecular characterization: Perspective of a multidisciplinary expert panelPublication . Fernandes, M. G. O.; Vilariça, A. S.; Fernandes, B.; Camacho, C.; Saraiva, C.; Estevinho, F.; Bastos, H. Novais e; Lopes, J. M.; Fidalgo, P.; Garrido, P.; Alves, S.; Silva, S.; Sequeira, T.; Barata, F.The management of NSCLC remains challenging, and the integration of data from predictive biomarkers in routine clinical practice can contribute to an optimal, individualized patient approach, particularly given the rapid emergence of effective targeted therapies. When considering molecular biomarker testing, the choice of the biomarker panel, target population, testing approach, and turnaround time are key issues that, when properly addressed, can improve the survival outcomes of NSCLC patients.